Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Carmustine sustained-release implantation agent for curing entity tumour

A slow-release implant, carmustine technology, applied in the field of medicine, can solve the problems of easy burst release, short drug release cycle, poor tumor cell effect, etc.

Inactive Publication Date: 2008-05-14
SHANDONG LANJIN PHARMA
View PDF7 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, the existing sustained-release agents use polyesters (polyesters) such as PLA and PLGA as sustained-release carriers, which have a short drug release cycle and have poor effects on tumor cells entering the dormant phase. Therefore, the effect on residual tumor cells The effect is poor, easy to burst release, so the toxicity is serious

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0080] Put the weighed slow-release auxiliary material (molecular weight is 15000-25000 PLGA, 50:50) and slow-release modifier (mannitol) into different containers respectively, then add a certain amount of organic solvent to dissolve and mix well (to fully dissolve prevail) and then add different weights of carmustine, re-shake and then vacuum-dry to remove the organic solvent. The dried solid sustained-release implant was immediately shaped to obtain the following sustained-release implant:

[0081] (A) 1% carmustine, containing 1mg carmustine, 99mg PLGA

[0082] (a) 1% carmustine, containing 1 mg carmustine, 95 mg PLGA, 4 mg mannitol;

[0083] (B) 5% carmustine, containing 5 mg carmustine, 95 mg PLGA;

[0084] (b) 5% carmustine, containing 5 mg carmustine, 91 mg PLGA, 4 mg mannitol;

[0085] (C) 10% carmustine, containing 10mg carmustine, 90mg PLGA;

[0086] (c) 10% carmustine, containing 10mg carmustine, 80mg PLGA, 10mg mannitol;

[0087] (D) 15% carmustine, containin...

Embodiment 2

[0092] 10 sustained-release implants in Example 1 were put into the dissolution apparatus respectively to measure the drug cumulative release amount (%) at different times, and it was found that in the sustained-release implants (A), (B), (C ), (D) and (E) five carmustine sustained-release implants that do not contain a sustained-release regulator (mannitol) have obvious burst release phenomenon, and the burst release phenomenon mostly occurs on the 26th-30th day. It accounts for about 40-60% of the total drug content, while (a), (b), (c), (d) and (e) and other carmustine slow-release implants containing slow-release regulators (mannitol) The burst release phenomenon of the medicine is obviously not obvious, and the medicine is released slowly for 3-5 weeks.

Embodiment 3

[0094] Put the weighed sustained-release auxiliary material (PLGA with a molecular weight of 20000-30000, 75:25) and the sustained-release regulator (mannitol) into different containers respectively, then add a certain amount of organic solvent to dissolve and mix (to fully Dissolution prevails) and then add different weights of carmustine, re-shake, and vacuum-dry to remove the organic solvent. The dried solid sustained-release implant was immediately shaped to obtain the following sustained-release implant:

[0095] (A) 1% carmustine, containing 1mg carmustine, 99mg PLGA

[0096] (a) 1% carmustine, containing 1 mg carmustine, 95 mg PLGA and 4 mg sorbitol;

[0097] (B) 5% carmustine, containing 5 mg carmustine, 95 mg PLGA;

[0098] (b) 5% carmustine, containing 5 mg carmustine, 91 mg PLGA and 4 mg sorbitol;

[0099] (C) 10% carmustine, containing 10mg carmustine, 90mg PLGA;

[0100] (c) 10% carmustine, containing 10 mg carmustine, 80 mg PLGA and 10% sorbitol;

[0101] (D) ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to a slow-release implant agent of carmustine, which is characterized by effective amounts of carmustine, slow-release excipients and releasing regulatory agents in the slow-release implant agent. The excipients comprise macromolecules which are biologically compatible and degradable, mainly PLA and PLGA. The releasing regulatory agents are selected from one or more items from mannitol, sorbitol, xylitol, oligosaccharide, chitin, potassium salt, sodium salt, hyaluronic acid, collagen, chondroitin, gelatin and albumin. The slow-release implant agent slowly releases carmustine on the local tumor in the process of degradation and absorption, so the argent can evidently reduce the systemic toxicity and simultaneously apply to the effective drug concentration control on the local tumor. Therefore, the argent can be applied separately or combined with the non-surgical treatments such as chemotherapy drug and radiotherapy, which can be also widely used for tumor treatment of different phases, not only selectively improving the drug concentration on local tumor but also reinforcing the therapeutic effect of non-surgical treatments such as chemotherapy drug and radiotherapy.

Description

(1) Technical field [0001] The invention relates to a carmustine sustained-release implant for treating solid tumors, belonging to the technical field of medicines. (2) Background technology [0002] Although the research on cancer has made great progress, its mortality rate is still in the forefront of various common causes of death. In my country, about 1.6 million people suffer from cancer every year, and nearly 1.3 million people die of cancer, accounting for one-fifth of the total death toll. The incidence of cancer is increasing year by year and tends to be younger. Statistics show that in less than 20 years, the incidence of cancer in my country has increased by 69%, and the mortality rate has increased by 29.4%. According to the latest statistics from the World Health Organization, the global cancer incidence rate will increase by 50% by 2020, and the number of patients will increase to 15 million. Therefore, exploring an effective method or drug for treating cance...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K9/00A61K31/17A61K47/34A61P35/00
Inventor 孙娟陈颖
Owner SHANDONG LANJIN PHARMA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com